Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adial PharmaceuticalsADIL +2.59%30 3-Year EBITDA Growth Rate is 65.00% as of Jun. 2026, which is 206% above its 10-year median of 21.25. GuruFocus rates ADIL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,129 Biotechnology companies, Adial Pharmaceuticals ranks better than 91.5% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 65.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 55.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adial Pharmaceuticals was 65.00% per year. The lowest was -115.80% per year. And the median was 21.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Adial Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
ADIL vs PULM, KAPA, ACXP: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Adial Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adial Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adial Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Adial Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 65.00% mean?
Adial Pharmaceuticals (ADIL) has a 3-Year EBITDA Growth Rate of 65.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adial Pharmaceuticals and its competitors. This is 206% above median its historical median of 21.25. According to the industry distribution chart, Adial Pharmaceuticals ranks #96 out of 1129 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Adial Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Adial Pharmaceuticals' current 3-Year EBITDA Growth Rate of 65.00% is 206% above median its 10-year median of 21.25. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Adial Pharmaceuticals' value of 65.00% is 336.2% above this industry median. Based on the distribution chart, Adial Pharmaceuticals ranks #96 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adial Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Adial Pharmaceuticals' 3-Year EBITDA Growth Rate compare to PULM and KAPA?
According to the Biotechnology industry distribution chart, Adial Pharmaceuticals ranks #96 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Adial Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Adial Pharmaceuticals' value of 65.00% is 336.2% above this benchmark. While the company's 10-year median is 21.25 vs. the industry median of 14.90, Adial Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adial Pharmaceuticals's current 3-Year EBITDA Growth Rate of 65.00% is 336.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adial Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adial Pharmaceuticals's current 3-Year EBITDA Growth Rate is 65.00%, which is 206% above median its own 10-year median of 21.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adial Pharmaceuticals stock overvalued right now?
Adial Pharmaceuticals (ADIL) has a current 3-Year EBITDA Growth Rate of 65.00%. The current 3-Year EBITDA Growth Rate is 65.00%, which is 206% above median its 10-year median of 21.25 and 336.2% above the Biotechnology industry median of 14.90. Adial Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Adial Pharmaceuticals (ADIL), the current 3-Year EBITDA Growth Rate is 65.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
30GF Score
Get the complete analysis for ADIL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIL has been successfully added to your 
